[Vitamin D treatment--which analogs and when?].
Chronic kidney disease is associated with a decreased production of the active metabolite of vitamin D, 1 alpha,25-Dihydroxy-Vitamin D. This decrease has several consequences which are not only restricted to the bones. Indeed, vitamin D has multiple actions which are discussed in this review. Vitamin D substitution is considered early in the treatment of chronic kidney disease but uncertainties about the type of substitution remain. The role of vitamin D analogs are reviewed with emphasis on the comparison between calcitriol and paricalcitol.
Martin
P-Y
PY
Service de Néphrologie, Département de Médecine Interne, Hôpitaux Universitaires de Genève, HUG, Genève. Pierre-yves.martin@hcuge.ch
Trombetti
A
A
Stoermann
C
C
D050197:Atherosclerosis / Q000188:drug therapy / Q000209:etiology; D002114:Calcinosis / Q000188:drug therapy / Q000209:etiology; D002117:Calcitriol / Q000627:therapeutic use; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000150:complications*; D006435:Renal Dialysis; D014807:Vitamin D / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D014808:Vitamin D Deficiency / Q000188:drug therapy*
D014807:Vitamin D; D002117:Calcitriol